Sentences with phrase «lymphocytic leukemia patients»

If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow - up strategies.

No improvement in long - term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets # 1 and # 2 treated with chemo (immuno) therapy

Not exact matches

A series of preliminary Mayo Clinic studies conducted in 2010 showed promise for the potential use of a chemical component of green tea (epigallocatechin gallate) in reducing the number of cancer cells in patients with chronic lymphocytic leukemia.

«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»

The authors conclude that FL118 - based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.

The new drug will now be tested in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma in an early stage clinical trial.

The FDA granted approval to rituximab and hyaluronidase (Rituxan Hycela) for patients with follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

Using a novel technique to genetically modify T cells for adoptive transfer, Carl June, Michael Kalos, David Porter, Bruce Levine, and colleagues at the University of Pennsylvania School of Medicine achieve clinical responses in patients with chronic lymphocytic leukemia, including two complete, durable (one year) clinical responses, accompanied by in vivo expansion and long - term functional persistence of gene - modified cells.

The FDA granted approval to ofatumumab (ARZERRA), a targeted antibody against CD20, for patients with chronic lymphocytic leukemia (CLL) who are in complete or partial response after at least two lines of therapy.

The targeted agent ibrutinib has shown a high response rate in both treatment - naive and previously treated, relapsed, refractory chronic lymphocytic leukemia (CLL) patients older than 65.

Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.

Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.

Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.

2/12/2008 Gene Therapy Protocol at UCSD Activates Immune System in Patients with Leukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tPatients with Leukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tLeukemia A research team at the Rebecca and John Moores UCSD Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tpatients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies tleukemia (CLL) who were treated with a gene therapy protocol began making antibodies that r...

As a long time chronic lymphocytic leukemia (CLL) cancer patient, Marty Smith has every reason to be bullish on cancer.

Ibrutinib is also approved to treat chronic lymphocytic leukemia / small lymphocytic lymphoma, including patients with 17p deletion, mantle cell lymphoma after at least one prior therapy, and patients with Waldenstrom macroglobulinemia.

Paul Insel, MD, professor of pharmacology and medicine, will investigate the expression of the GPCR family of receptors on the surface of cells from patients with chronic lymphocytic leukemia (CLL).

In 2011, Carl H. June, M.D. (a CRI clinical investigator and member of the CRI Scientific Advisory Council), Michael Kalos, Ph.D. (a former CRI postdoctoral fellow and member of the CRI Scientific Advisory Council), and colleagues at the University of Pennsylvania School of Medicine achieved good clinical responses in patients with chronic lymphocytic leukemia (CLL), including two complete, durable clinical responses.

The lab chose to use the TCL1 mouse model to study B - cell leukemia because ~ 90 percent of human chronic lymphocytic leukemia (CLL) patients express the TCL1 protein, and the overexpression of TCL1 in B cells leads to the development of CLL in mice.

Another team used personalized cellular therapy to cure chronic lymphocytic leukemia in patients.

Patients with Crohn's disease, psoriasis, rheumatoid arthritis, B cell lymphoma and chronic lymphocytic leukemia have also developed the devastating brain disease after immunosuppressant therapy with natalizumab and other drugs.

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

B - cell chronic lymphocytic leukemia (B - CLL) is a common cancer in dogs, but little is known about the disease, including its clinical progression and survival expectations for patients.

Researchers will identify potential treatment targets for B - cell chronic lymphocytic leukemia in dogs and ways to identify high - risk patients.

Among patients with relapsed / refractory chronic lymphocytic leukemia, those who have higher stress related to their cancer experience at the start of treatment have worse psychological functioning during the first five months of treatment.

Findings suggest cancer - specific stress at treatment initiation may be a risk factor for poorer psychological functioning during treatment for patients with relapsed / refractory chronic lymphocytic leukemia.

To examine cancer - specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed / refractory chronic lymphocytic leukemia during the first 5 months of treatment.

Little is known about the psychological and physical functioning of patients with relapsed / refractory chronic lymphocytic leukemia.